This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
the annual probability of death whilst on dialysis on the transplant waiting list and not on the waiting list; the annual probability of complications on home and hospital dialysis; the time to transplantation with donor and cadaver donors; the annual death rates and graft loss rates following live donor transplant and cadaveric transplant; and the delay in starting home dialysis.
Study designs and other criteria for inclusion in the review
Not reported.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Approximately 11 primary studies were used to identify model parameters.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The following model parameters were taken from published papers: the annual probability of transferring from home dialysis to hospital dialysis was 5%; the annual probability of death whilst on dialysis on the transplant waiting list was 6.3%; the annual probability of death whilst not on the transplant waiting list was 16.1%; the annual probability of complications on home dialysis was 3.1%; the annual probability of complications on hospital dialysis was 12.8%; the time to transplantation with a live donor was 0.8 years; the time to transplantation with a deceased donor was 5 years;
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Page: 2 / 6 the delay in starting home dialysis was 260 weeks; the annual death rate following a live donor transplant was between 1 and 2%; the annual death rate following a cadaveric donor transplant was between 2.8 and 6%; the annual post transplantation graft loss with a live donor was between 1 and 6%; and the annual post transplantation graft loss with a cadaveric donor was between 0.4 and 12%.
Methods used to derive estimates of effectiveness
Some model parameters were either taken from the study hospital or estimated by the authors.
Estimates of effectiveness and key assumptions
The authors made the following estimations:
the weekly probability of death from home dialysis complications was 10%;
the weekly probability of resolution of home dialysis complications was 80%;
the proportion of patients eligible for transplantation was 50%; and the proportion of transplantations from live donors was 33%.
Measure of benefits used in the economic analysis
The summary measure of health benefits used was the quality-adjusted life-years (QALYs). Utility weights were taken from another study conducted by the authors. No further details of the methods used to derive the utility weights were provided. Future health benefits were discounted at a rate of 3% per annum.
Direct costs
The direct costs of the health care payer were estimated. These included the costs of dialysis, complications from dialysis, and transplantations. Resource use was estimated using the model described. The unit costs were taken from the literature. Health care costs associated with conditions other than renal failure were not included in the study. The price year was 2003. Future costs were discounted at a rate of 3% per annum.
Statistical analysis of costs
The cost data were treated deterministically.
Indirect Costs
No indirect costs were included in the study.
Currency
Canadian dollars (CAD).
Sensitivity analysis
A series of one-way sensitivity analyses were performed to assess uncertainty in the data. The ranges used in the sensitivity analyses were taken from the literature. A Monte Carlo sensitivity analysis was undertaken (1,000 iterations). The parameter means, errors and distributions were presented in the paper.
Validity of estimate of measure of effectiveness
The effectiveness data used as model input parameters were taken from the literature or, when necessary, estimated by the authors. There were no details of the methods used to identify the primary studies or assess their quality. Also, no details were provided of how the authors combined or selected their estimates of model parameters. This lack of detail means it is difficult to comment on the quality of the methods used to obtain the model parameters. Further, the authors acknowledged that some of the cohort studies used to identify model parameters might have been subject to survival bias. However, the extent of variability in the data was fully assessed through the Monte Carlo simulation.
Validity of estimate of measure of benefit
The measure of health benefit was derived from the model. The use of QALYs allows comparisons between the two treatments considered in this study, and well as other interventions for other conditions. The health benefits were discounted at the same rate as that used for the costs.
Validity of estimate of costs
This study adopted the perspective of a health care payer. The authors indicated that health care costs associated with conditions other than renal failure were not included in the estimate. The costs associated with dialysis, complications from dialysis, and transplantation were included in the study. The authors noted health care costs incurred because of conditions unrelated to ESRD were assumed to be equal in both groups. They reported that these patients were likely to have fewer co-morbidities than hospital-based dialysis patients, so these costs were likely to be lower in HNHD dialysis patients. Therefore, this omission is unlikely to have altered the study findings. The extent of variability and uncertainty in the data was assessed through comprehensive sensitivity analyses and a Monte Carlo analysis. Future costs were appropriately discounted. These factors add to the generalisability of the study findings. However, no breakdown of resource use and unit costs was provided, which detracts from the generalisability of the study. A clear price year was
